Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Liabilities
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison
600436
600276
000538
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Other Current Liabilities
¥181.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Current Liabilities
¥530.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Current Liabilities
¥450.5m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Current Liabilities
¥721.4m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Other Current Liabilities
¥3.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Current Liabilities
¥101.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
181.4m
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities amounts to 181.4m CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
9%
Over the last year, the Other Current Liabilities growth was -17%. The average annual Other Current Liabilities growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 6% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
